Skip to content
The Intraday
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

AMPH Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

AMPH
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

AMPH Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

Amphastar Pharmaceuticals, Inc.

AMPH
$20.42
+$0.11 (0.54%)+0.54%
Closed
Loading chart...
IndexN/A
Market Cap0.90B
Enterprise Value1.74B
Income$0.03B
Sales$0.17B
EmployeesN/A
P/E6.97
P/S1.74
P/B1.59
P/C10.33
EV/EBITDA8.18
EV/SalesN/A
EPS (ttm)2.93
EarningsN/A
Gross Margin49.46%
Oper. Margin19.50%
Profit Margin13.63%
Volume0.34M
Shs Outstand0.04B
Change0.54%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$731.97M$644.39M$498.99M$437.77M$349.85M$322.36M$294.67M$240.18M
Cost of Revenue$358.11M$293.27M$250.13M$238.03M$206.51M$190.43M$187.68M$149.38M
Gross Profit$373.86M$351.12M$248.86M$199.74M$143.34M$131.92M$106.98M$90.80M
Gross Margin51.08%54.49%49.87%45.63%40.97%40.92%36.31%37.80%
Operating Expenses$168.44M$154.13M$141.36M$129.85M$132.39M$131.96M$115.61M$91.69M
Operating Income$205.42M$196.99M$107.50M$69.89M$10.95M$-39.00K$-8.62M$-895.00K
Operating Margin28.06%30.57%21.54%15.96%3.13%-0.01%-2.93%-0.37%
Net Income$159.52M$137.54M$91.39M$62.12M$1.40M$48.94M$-5.74M$4.51M
Net Margin21.79%21.34%18.31%14.19%0.40%15.18%-1.95%1.88%
EPS (Basic)$3.29$2.85$1.88$1.30$0.03$1.04$-0.12$0.10
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$1.58B$1.51B$741.99M$671.53M$631.24M$586.97M$513.56M$454.67M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$845.17M$873.49M$213.33M$226.01M$182.51M$159.44M$149.20M$117.34M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$732.30M$639.42M$528.66M$445.52M$402.31M$381.37M$332.44M$337.33M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$732.30M$639.42M$528.66M$445.52M$402.31M$381.37M$332.44M$337.33M
Total Liabilities & Stockholders Equity$1.58B$1.51B$741.99M$671.53M$631.24M$586.97M$513.56M$454.67M
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$159.52M$137.54M$91.39M$62.12M$1.40M$48.94M$-5.74M$4.51M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$213.39M$183.50M$89.18M$97.99M$57.27M$41.76M$38.19M$39.21M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Aug 7 · 12:44AMAmphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcriptseekingalpha.com ↗Aug 6 · 8:31PMCompared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metricszacks.com ↗Aug 6 · 7:04PMAmphastar Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com ↗Aug 6 · 4:05PMAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026prnewswire.com ↗Jul 29 · 6:00AMAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026prnewswire.com ↗Jul 22 · 9:16AMTrump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplycnbc.com ↗Jun 23 · 6:16AMNew Strong Sell Stocks for June 23rdzacks.com ↗Jun 10 · 7:09PMAmphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growthmarketbeat.com ↗
Show 12 more stories↓
Jun 8 · 8:19AMAmphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Lossesglobenewswire.com ↗Jun 4 · 12:02AMAmphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Dragmarketbeat.com ↗May 27 · 6:00AMAmphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conferenceaccessnewswire.com ↗May 14 · 2:06AMAmphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlookmarketbeat.com ↗May 13 · 8:50PMAmphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com ↗May 8 · 6:41AMAmphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcriptseekingalpha.com ↗May 7 · 9:01PMCompared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metricszacks.com ↗May 7 · 6:55PMAmphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimateszacks.com ↗May 7 · 4:05PMAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026accessnewswire.com ↗May 6 · 6:00AMAmphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conferenceaccessnewswire.com ↗Apr 30 · 6:00AMAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026accessnewswire.com ↗Apr 29 · 12:41PMAMPH vs. RDY: Which Stock Should Value Investors Buy Now?zacks.com ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Richard Prins
Sell
8.0K
$20.31
$162K
Aug 11, 26
PETERS WILLIAM J
Option
5.1K
$19.79
$100K
Aug 7, 26
PETERS WILLIAM J
Sell
8.2K
$22.48
$184K
Aug 7, 26
Pierce Anthony T
Award
16.6K
$19.02
$317K
Jul 9, 26
Deflin Gayle
Award
8.1K
—
—
Jun 1, 26

Company

CEO: Yongfeng ZhangEmployees: 1976www.amphastar.com
About the company↓

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Discover more

You may be interested in
TSLA

Tesla Inc

$332.81

↑ 0.58%
NVDA

NVIDIA Corp

$217.50

↓ 0.02%
ORCL

Oracle Corp

$145.44

↓ 3.71%
V

Visa Inc

$362.82

↑ 0.60%
INTC

Intel Corp

$97.71

↑ 0.19%
JPM

JPMorgan Chase & Co

$362.04

↑ 0.63%
BAC

Bank of America Corp

$64.00

↑ 0.22%
DIS

Walt Disney Co

$103.51

↑ 0.32%
ABX

Abacus Global Management Inc

$8.92

↓ 6.30%
MA

Mastercard Inc

$561.44

↓ 0.31%
IBM

IBM Corp

$238.42

↑ 0.89%
AMD

Advanced Micro Devices

$474.32

↑ 1.01%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC